are subject to bias from differences in trial design, including heterogeneity in patient populations due to differences in patient inclusion and exclusion criteria (6, 7).
Matching-adjusted indirect comparison (MAIC)
is an analytical method for an indirect comparison that uses a form of propensity score weighting of individual patient data (IPD) to match patients from one trial with those from another for baseline characteristics, especially those that may influence treatment response (8, 9). By reweighting patient data, MAIC targets comparison of treatment efficacy in the matched population, reducing the impact of heterogeneity between study populations. This technique has been increasingly used in the area of spondyloarthritides, as well as other diseases (8-12), and is an accepted technique used by agencies, such as the UK's National Institute for Health and Care Excellence (NICE) in their decision-making processes (13-16).
Our study follows the NICE guidelines on MAIC methodology [Decision Support Unit (DSU) Technical Support Document (TSD) 18] (14, 17) and provides evidence for comparative effectiveness of medium-term (≤1 year) biologic therapy for biologic-naïve patients with active AS. We compared the TNFi adalimumab with secukinumab, using common primary and secondary outcome measures from the pivotal phase 3 RCTs. Selection of baseline characteristics for matching Selection of matching variables complied with NICE DSU TSD 18 (14, 17), following (1) advice from clinical experts in the treatment of AS, (2) a review of the clinical literature, and (3) statistical analyses of prognostic variables and effect modifiers using logistic regression analysis (Supplementary Table  3 ) (14, 17), as described previously (9).
The principal analysis matched for previous use of TNFi therapy, age, sex, mean Bath Ankylosing Spondylitis Functional Index (BASFI) score, and mean C-reactive protein (CRP) level (Supplementary Table 4 ). A sensitivity analysis additionally included mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score as a baseline matching variable.
Matching and adjustment of IPD to published aggregate data Three MAIC analyses against ATLAS were developed: pooled MEASURE 1/2, MEASURE 1 individually, and MEASURE 2 individually. The pooled MEASURE 1/2 analysis is presented in our study because it has the largest effective sample size (ESS). Patients receiving secukinumab in each MEASURE study were matched to patients in ATLAS; results are therefore targeted to a population similar to ATLAS ( Figure  1 ). For post-matching, the MEASURE secukinumab 150 mg population was compared with the adalimumab arm of ATLAS because 150 mg is the licensed secukinumab dose in AS (4, 21). The methodology for matching and adjustment was based on Signorovitch et al. (12) and subsequent studies (11, 15, 30) and is in line with NICE DSU TSD 18 (11, 14, 15, 17, 22) . Regression results were used to weight patients in the MEASURE trials, so that each patient's weighting corresponded to their relative propensity to match with ATLAS for those variables considered treatment effect modifiers (age, sex, BASFI, CRP, and prior TNFi exposure).
Comparison of outcomes using weighted patient data The weights were used to recalculate outcomes for each patient. Outcomes were then aggregated and used to estimate the comparative effectiveness of secukinumab and adalimumab (15).
Analyses

Missing data
In the ATLAS trial, missing data for all binary outcomes (ASAS 20, ASAS 40, and ≥50% improvement in BASDAI score) were imputed using non-responder imputation (NRI) up to week 24. After week 24, last observation carried forward (LOCF) data were reported for patients who had switched to adalimumab weekly, used early escape therapy, or switched from Figure 1 . Matching-adjusted indirect comparison using pooled MEASURE 1 and MEASURE 2 data as an example *An MAIC was similarly performed for MEASURE 2 only, in which the pooled secukinumab 75 mg and 150 mg arms were matched; however, outcome data are shown only for secukinumab 150 mg placebo (19, 20) . LOCF was used for all continuous outcomes. In both MEASURE studies, missing data for binary outcomes were imputed by NRI at all time points (18). Between-group differences in continuous variables were evaluated using a mixed-model repeated-measures approach. To compensate for these differences and to match the ATLAS design for missing data as closely as possible (19, 20), week 52 data from both MEASURE studies were recalculated using LOCF and included placebo switchers to the 150 mg dose. Missing continuous outcomes from both MEASURE studies were calculated to match ATLAS using LOCF. If AT-LAS data were reported in graphs only, specific software (DigitizeIt, Braunschweig, Germany) was used for data extraction.
Placebo-adjusted and non-placebo-adjusted outcome comparisons At weeks 8 and 12, anchored (placebo-adjusted) comparisons were possible. Placebo-adjusted comparisons were not possible after week 12 because patients randomized to placebo could receive active treatment from week 16 in MEASURE 1/2 and from week 12 in ATLAS (Supplementary Figure 2) . Therefore, after week 12, outcomes from the adalimumab arm of ATLAS were directly compared with outcomes from the adjusted and recalculated pooled secukinumab 150 mg arms of MEA-SURE 1/2. This unanchored (non-placebo-adjusted) MAIC methodology is recommended by NICE in cases when anchored comparisons are not possible (14, 17, 22-24).
Pairwise comparisons
For the ASAS 20, ASAS 40, ASAS 5/6, and ASAS partial remission (PR) outcomes, odds ratios (ORs) were estimated along with their corresponding 95% confidence intervals (CIs) and p values (two-sided). Relative likelihoods of response (RRs) were also calculated for all ASAS responses (Supplementary Table 5 ). For placebo-adjusted comparisons, ORs and corresponding standard errors were calculated using the Bucher method (7). For non-placebo-adjusted comparisons, standard errors for OR values were estimated based on the information provided by a 2×2 contingency table that shows outcomes in the adalimumab arm of the ATLAS trial and outcomes in the recalculated pooled secukinumab 150 mg arm of MEASURE 1/2.
Continuous outcome scores
Comparisons for continuous outcomes were made at week 12 (placebo-adjusted) and weeks 24 and 52 (non-placebo-adjusted). For placebo-adjusted comparisons, differences in mean scores between adalimumab and placebo and secukinumab and placebo, respectively, were calculated, along with 95% CIs and p values based on a normal approximation. For non-placebo-adjusted comparisons, the mean change scores of patients in the adalimumab arm of the ATLAS trial were compared with the mean change scores of patients in the reweighted secukinumab arms of the MEASURE 1/2 population. Normal approximations were used to calculate 95% CIs; however, complete week 52 data were not reported from ATLAS, and it was therefore not possible to calculate p values.
For all ASAS and continuous outcome scores, the commonly used threshold of p<0.05 was considered the threshold for statistical significance. In acknowledgment of the recent American Statistical Association (ASA) guidelines (25, 26), ASAS data were also interpreted using a more modern definition of statistical evidence (27, 28), as described previously (9). Figure 1 illustrates the MAIC matching process. Supplementary Table 4 shows the baseline characteristics of patients in MEASURE 1/2 in the pooled secukinumab 150 mg (n=197) and placebo arms (n=196) before and after matching to the ATLAS adalimumab 40 mg (n=208) and placebo arms (n=107). Before matching, there was heterogeneity between the trial populations. In addition to demographic characteristics, an important difference between populations was that 31.0% of patients randomized to secukinumab were TNFi-inadequate responders (TNFi-IR; 69.0% were TNFi-naïve), whereas all patients receiving adalimumab were TNFi-naïve. After matching, all patients receiving secukinumab were TNFi-naïve. Achieving homogeneity between the two populations reduced the sample size the ESS of pooled MEASURE 1/2 after matching was 120 for secukinumab 150 mg and 120 for placebo. Figure 2 , Table 1 , and Supplementary Figure 3 show the ASAS response rates in the principal analysis. At weeks 8 and 12, patients receiving adalimumab had numerically higher placebo-adjusted ASAS 20, 40, 5/6, and PR response rates than those receiving secukinumab; however, there were no significant differences (p>0.05). Compared with adalimumab, at week 16, the ASAS 20 response rate was significantly higher for patients receiving secukinumab [OR Table 5 ).
Results
Principal analysis Matching baseline characteristics
ASAS response rates
Using an additional interpretation of data acknowledging the recent ASA guidelines yielded similar observations (Supplementary Table 6 ). ASAS 20 response rates in patients receiving placebo were 29.0% (ATLAS; aggregate data) and 32.3% (MEASURE 1/2; after matching) at week 8 and 20.6% (ATLAS; aggregate data) and 33.7% (MEASURE 1/2; after matching) at week 12; ASAS 40 response rates were 13.1% (ATLAS; aggregate data) and 16.7% (MEASURE 1/2; after matching) at week 12. Given that ASAS 40 is a more stringent outcome than ASAS 20, the near equivalence of the ASAS 40 placebo response between ATLAS and recalculated rates from MEASURE 1/2 suggests a good match. Supplementary Table 7 shows placebo responses from principal and sensitivity analyses. Table 6 shows an additional interpretation of data acknowledging the recent ASA guidelines.
Continuous outcome
Continuous outcome scores
The sensitivity analysis demonstrated significant improvements in total back pain, nocturnal pain, BASDAI fatigue, and tender and swollen joint counts for secukinumab compared with adalimumab, and in PtGA, BASFI, BASMI, and BASDAI inflammation scores for adalimumab compared with secukinumab (Supplementary Table 8 ).
Individual MEASURE 1 and MEASURE 2 MAIC study analyses versus ATLAS As shown in Figures 3 and 4 , separately matching individual MEASURE 1 (secukinumab 150 mg ESS=88 and placebo ESS=82) or MEASURE 2 (secukinumab 150 mg ESS=34 and placebo ESS=34) data gave similar results to the pooled MEASURE 1/2 analysis. In the MEASURE 2 analysis, in which patients received the licensed dosing with subcutaneous loading, we identified additional evidence for a significantly higher ASAS 20 response with secukinumab than that with adalimumab at week 8 [OR 3.38 
Discussion
This MAIC demonstrated no significant differences in placebo-adjusted ASAS 20 and 40 responses up to 12 weeks between secukinumab-and adalimumab-treated patients with AS who were matched for treatment effect modifiers (age, sex, BASFI, CRP, and prior TNFi exposure). Our data suggest that patients with AS treated with secukinumab may be more likely to experience ASAS 20 responses than those treated with adalimumab after week 12. In the pooled MEASURE 1/2 analysis, the strongest statistical evidence supporting higher ASAS responses (ASAS 20 and 40) in patients treated with secukinumab was observed at weeks 24 and 52, suggesting that secukinumab might provide further treatment responses with prolonged therapy.
Taken together, our analyses provide evidence that TNFi-naïve patients with active AS receiving secukinumab 150 mg achieve similar short-term (weeks 8 and 12, placebo-adjusted) and medium-to long-term (weeks 16, 24, and 52, non-placebo-adjusted) reductions in signs and symptoms to those receiving adalimumab 40 mg.
Patient-reported outcomes are central to understanding how any therapeutic agent impacts a patient's ability to function and to perform daily activities. At week 24, we observed that the majority of significantly improved disease activity scores (i.e., total back pain, nocturnal back pain, tender joint count, and swollen joint count) were reported by patients treated with secukinumab. Additionally, we observed several improved week 12 scores (e.g., PtGA, BASFI, BASDAI inflammation, and BASMI) with adalimumab relative to secukinumab. These findings could reflect differences in patient populations, multiplicity, or real differences in outcome domains relative to axial versus peripheral inflammation.
Our study has certain potential limitations, both inherent to the methodology and specific to our analysis. Despite matching observed patient variables considered treatment effect modifiers at baseline, unobserved variables or variables reported by only one study cannot be controlled via MAIC. We also present non-placebo-adjusted comparisons that, while providing a transparent way to compare longterm data, are conducted in a non-random- ized fashion at time points when patients are aware of their biologic treatment. We also used pooled IPD from MEASURE 1 and MEASURE 2 to allow an increased ESS, although there were differences in the design of these two trials, including the intravenous loading regimen used in MEASURE 1 (secukinumab 10 mg/kg body weight or placebo sham infusion) versus subcutaneous used in MEASURE 2 (secukinumab 75 mg or 150 mg or placebo subcutaneous doses). However, we consider this acceptable because the MEASURE 1 and 2 data sets were also interrogated individually by MAIC, free from composite mean data bias, and showed results similar to the pooled analysis. Of note, it was only possible to adjust for characteristics that were reported and defined in the same way across the included RCTs. Methods to quantify the remaining unexplained heterogeneity (e.g., associated with study design, conduct, or patient eligibility) in MAICs are an important area of future research. Moreover, the MAIC analysis was restricted to TNFi-naïve patients. Differences between outcomes tended to be small in this MAIC with sometimes marginal statistical significance. Finally, another limitation of this MAIC is that we did not compare safety outcomes between treatments.
There has been one previous MAIC between secukinumab and adalimumab, which compared ASAS 20 and ASAS 40 responses at week 12 (ATLAS) with those at week 16 (MEASURE 1/2) and showed similar efficacy between the two agents, even though the biologic-naïve cohort of ATLAS was compared with a mixed population of biologic-naïve and biologic-experienced patients from MEASURE 1/2 (10). Based on our regression model, TNFi-IR patients were less likely to achieve ASAS 20 responses with secukinumab in MEASURE 1/2 than those who were TNFi-naïve [OR 0.545 (95% CI, 0.33-0.92); p=0.022]. A similar relationship has been shown between ASAS 40 responses to adalimumab in TNFi-naïve and TNFi-IR patients (31). Thus, not matching for TNFi use is expected to lead to a strong potential for bias in favor of adalimumab. Despite this bias, the previous MAIC showed no significant difference between secukinumab and adalimumab at weeks 12 and 16. In contrast, in the current MAIC, we used data that were matched for prior TNFi exposure.
In conclusion, the current MAIC of patients with active AS in the MEASURE 1/2 RCTs receiving secukinumab 150 mg who were matched for treatment effect modifiers to the ATLAS RCT population receiving adalimumab demonstrates comparable placebo-adjusted ASAS 20 and 40 responses up to 12 weeks but suggests a higher probability of achieving both mediumand long-term ASAS-defined responses (ASAS 20 and ASAS 40) in those receiving secukinumab. The authors are not aware of a planned or ongoing head-to-head RCT powered for superiority of AS sign and symptom improvement of secukinumab over adalimumab. However, a currently recruiting head-to-head RCT, SURPASS (NCT03259074), is powered for superiority of secukinumab over the adalimumab biosimilar GP2017 regarding the primary end-point of no radiographic structural progression of the spine (32). This will allow the direct comparison of secukinumab with an adalimumab biosimilar for an important clinical end-point.
Ethics Committee Approval: This study was of non-interventional nature and did not include primary data collection (i.e. was based on published secondary data only). Therefore, ethic committee or institutional review board approval was not required. Data used were taken from published randomized controlled trials, which were conducted according to the principles of the Declaration of Helsinki and with informed consent from participants. In line with the original review, systematic reviews, meta-analyses, and pooled analyses will be included at the title/abstract screening stage and used for identification of any additional primary studies not identified through the database searches, but will be excluded during the full- , mean (SD) 6.5 (2.0) 6.7 (1.9) 6.8 (1.6) 6.9 (1.7) 6.5 (1.3) 6.7 (1.4) 6.6 (1.2) 6.5 (1. (-3.5 to -2.6) (-3.5 to -2.9) p=0.004 BASDAI, 0-100 mm VAS -1.8 -1.5 -2.6 -3.1 -3.0 (NR) -2.9 (-2.4 to -1.2) (-1.9 to -1.1) (-3.0 to -2.2) (-3.3 to -2. Figure 2 . MEASURE 1, MEASURE 2, and ATLAS trial designs MEASURE 1 and 2 were phase 3 RCTs (18) in which patients who were refractory to NSAID therapy as defined by ASAS recommendations were recruited. Patients were also eligible if they had previously inadequately responded to ≥3 months of treatment with an approved dose of one TNFi (primary or secondary lack of efficacy); these accounted for 27.0% and 39.7% of the respective patient populations. Patients receiving placebo who did not achieve an ASAS20 response by week 16 were re-randomized 1:1 to secukinumab 75 mg or 150 mg; those who achieved responses were re-randomized 1:1 at week 24. In MEASURE 1, secukinumab was administered as an intravenous loading dose (10 mg/kg body weight) at weeks 0, 2, and 4, then subcutaneously (75 mg or 150 mg) every 4 weeks starting from week 8; in MEASURE 2, secukinumab was given subcutaneously (75 mg or 150 mg) at weeks 0, 1, 2, and 3, and every 4 weeks starting from week 4. ATLAS was a phase 3 RCT that recruited NSAID-refractory patients (19, 20); patients were ineligible if they had received any TNFi therapy. Adalimumab was given subcutaneously (40 mg) every other week. Patients receiving placebo without ASAS 20 responses at week 12, 16, or 20 were eligible for "early escape" to receive open-label treatment with adalimumab; all patients were eligible from week 24, with an option to uptitrate to weekly adalimumab (19, 20) . Across trials, the primary end-point was the proportion of ASAS 20 responders -at week 16 for MEASURE 1 and 2, and at week 12 for ATLAS. The predominant difference between ATLAS and MEASURE trials was that the latter included patients for whom a previous TNFi treatment had failed, while participants in the ATLAS trial were TNFi-naïve. 296 patients completed the double-blind phase and were eligible to enter the open-label extension. Post-week 24 efficacy data used in our MAIC analysis used published LOCF data of ATLAS patients who received at least one dose of adalimumab (n=311, of whom 239 received adalimumab EOW and 72 received adalimumab weekly). Placebo-adjusted comparisons were possible only up to week 12 because patients in ATLAS who did not achieve an ASAS 20 response were eligible for early escape (open-label adalimumab) from week 12 to week 24 (the cumulative number of patients entering early escape from each arm is indicated in red numerals; patients who withdrew from the study are not shown). Reference numbering in this figure caption is from the main paper
